From left to right: Stéphane Roulon (CEO MB Therapeutics), Frédéric Rimattei (DG CHU of Nîmes), Ian Soulairol (Scientific Director MB Therapeutics), Philippe Augé (President University of Montpellier), Philippe Combette (Director of Innovation University of Montpellier)

Blog

Blog

MB Therapeutics: 3D printing of medicines at the heart of the region

From left to right: Stéphane Roulon (CEO MB Therapeutics), Frédéric Rimattei (DG CHU of Nîmes), Ian Soulairol (Scientific Director MB Therapeutics), Philippe Augé (President University of Montpellier), Philippe Combette (Director of Innovation University of Montpellier)

Innovation in the pharmaceutical sector is a collective journey. At MB Therapeutics, our mission is to transform patient care through the 3D printing of medicines. Recently, we welcomed key players from our region for a strategic milestone update on our development.


Leading institutional and academic partners

We welcomed a visit to our premises from Philippe Augé (President of the University of Montpellier), Philippe Combette (Innovation Director of the UM), and Frédéric Rimattei (Director General of the Nîmes University Hospital). They were accompanied by Fabrice Salemi and Maxime Thorel, representatives of the Occitanie / Pyrénées Méditerranée Region, in connection with Vice-President Jalil Benabdillah.

 

A journey marked by regional excellence

This meeting highlighted the key milestones structural to our growth:

  1. Academic anchoring: A solid partnership established from our beginnings through a hosting agreement with the University of Montpellier before moving into our new premises.

  2. Clinical validation: Close and concrete collaboration with the Nîmes University Hospital.

  3. National recognition: Our selection as a regional winner of France 2030, a major support for industrial innovation in healthcare.

 

3D printing serving the patient

This exchange illustrates the importance of the links between university research, the hospital environment, and institutions in transforming innovation into concrete solutions for patients.